Even if therapeutic levels of CXCL14 could be clinically attained, the local application of CXCL14 to (or from) a single tumor site may not instigate an adequate immune response to promote cancer clearance in patients with advanced metastatic disease. The gene discussed is CXCL14; the disease is neoplasm.